← All trials
NCT06507618
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 19, 2024
- Primary completion
- Jun 30, 2029
- Completion date
- Mar 1, 2034
- First posted
- Jul 18, 2024
- Last posted
- Aug 21, 2024
- Enrollment
- 354
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of VirginiaLead sponsor
- University of VirginiaOfficial
- University of VirginiaSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.